Editorial abstract cover illustrating UAE Healthcare Market: Trends & Opportunities 2025
    Back to Blog
    Market Intelligence

    UAE Healthcare Market Trends 2025: What Pharma Teams Learned

    D
    Dina IbrahimResearch Director, BioNixus Healthcare Market Research
    4 Feb 2025
    8 min
    United Arab Emirates
    UAE HealthcareMarket TrendsMOHAPDHADOH
    Share:

    2025 was the year many Gulf launch plans stopped treating the United Arab Emirates as a single market. Federal registration through the Ministry of Health and Prevention (MOHAP) remained the legal gateway, but volume followed emirate-level formularies, insurance rules, and hospital-group procurement in Dubai and Abu Dhabi. BioNixus keeps this page as the 2025 UAE healthcare trends archive — the URL is unchanged — and has rewritten the body so it is actually about the Emirates rather than a recycled GCC template. For the current commercial agenda, read UAE healthcare market trends 2026. Country fieldwork design sits on the healthcare market research hub and the UAE country research page.

    Why 2025 still matters

    Search demand for “UAE healthcare market trends 2025” did not disappear when the calendar flipped. Access teams still use 2025 as the baseline year for insurance coverage, medical-tourism mix, and dual-emirate listing sequences. BioNixus therefore keeps this slug live, refreshes the article on 31 August 2026, and uses it as the historical spoke next to the UAE healthcare market report (sizing) and the UAE healthcare market overview 2026 (hospital and sales landscape).

    What 2025 was not: a Saudi analogue. SFDA registration and NUPCO tendering govern the Kingdom. They do not govern Dubai or Abu Dhabi. Any 2025 briefing that mixed those acronyms into a UAE narrative was describing the wrong country — which is why this page was rebuilt.

    Triple-regulator access in practice

    Three authorities shaped every 2025 launch calendar:

    • MOHAP — federal drug and device registration, list-price approval, and post-marketing surveillance. Without MOHAP, nothing is legally on the market.
    • Dubai Health Authority (DHA) — facility licensing, Dubai formulary and insurance rules (including the Essential Benefits Plan), and the private-hospital density that makes Dubai the commercial hub.
    • Department of Health – Abu Dhabi (DOH) — Abu Dhabi formulary and insurance logic (including Thiqa for nationals), plus the SEHA public hospital network and Mubadala Health / Cleveland Clinic Abu Dhabi tertiary demand.

    The operational consequence in 2025 was dual-pathway work: a MOHAP dossier plus separate DHA and DOH evidence packs. BioNixus documents that split in the Abu Dhabi DOH vs Dubai DHA formulary guide and the UAE market access strategy article. Research programmes that averaged “UAE physicians” without stratifying by emirate and sector produced forecasts that finance teams could not defend.

    Insurance, private spend, and medical tourism

    Mandatory health insurance across the seven emirates made 2025 a payer year, not only a hospital-capacity year. BioNixus sizes private-sector spend at roughly 65% of total UAE healthcare expenditure. That mix is why retailer and private-hospital channels each matter as much as government formularies, and why employer-plan tiers in Dubai and Abu Dhabi create different price-sensitivity profiles than a blended national average.

    Medical tourism amplified the same concentration: the UAE attracted over 350,000 medical tourists in 2025. High-acuity oncology, cardiology, and elective specialty volume clustered in flagship centres rather than spreading evenly across emirates. For insight teams, that meant named-institution samples (Cleveland Clinic Abu Dhabi, Dubai Healthcare City, Mediclinic, Aster, NMC) beat anonymous “UAE hospital” cells.

    Specialty demand that showed up in 2025

    2025 did not invent UAE specialty demand, but it made the therapy mix visible in commercial plans. Oncology, diabetes, and immunology were already the three largest pharmaceutical therapy areas by value going into 2026. Biosimilar policy in Abu Dhabi (DOH’s 2024 biosimilar guidance taking effect in August 2024) started to change switching conversations in immunology and supportive care. Rare-disease and genomics programmes continued to pull high-cost therapies into a small diagnosed-and-funded pool rather than a prevalence-based forecast.

    Those therapy-level numbers belong in dedicated reports — see the UAE healthcare market report and BioNixus therapy reports for oncology, immunology, biosimilars, and rare disease. This trends page only records the 2025 pattern: specialty value grew faster than primary-care volume, and it grew inside insurance and flagship-hospital gates.

    What 2025 taught insight and access teams

    1. Do not collapse Dubai and Abu Dhabi. Formulary logic, insurance mix, and tertiary referral paths differ. Stratify samples and evidence packs.
    2. Sequence MOHAP, then DHA and DOH. Federal registration is necessary and not sufficient. Build listing calendars per emirate.
    3. Use claims and e-claims context, then ask what claims cannot answer. Dubai’s utilisation reporting is unusually rich for the region; primary research should target physician rationale, tumour-board influence, and pharmacy-and-therapeutics objections.
    4. Bilingual fieldwork is not optional. Arabic clinical idiom and English affiliate reporting need to live in the same instrument, not in a translation afterthought.
    5. Keep Saudi and UAE workstreams separate. SFDA/NUPCO evidence does not substitute for MOHAP/DHA/DOH evidence.

    Those lessons are the brief BioNixus still uses when a 2026 tracker is calibrated against a 2025 baseline.

    How BioNixus uses the 2025 record

    BioNixus designs UAE programmes with shared governance and emirate-specific sampling: physician and payer interviews across DHA-licensed and DOH-licensed facilities, KOL maps that name SEHA and private groups separately, and access narratives that do not recycle Saudi tender language. Pair this archive with UAE healthcare market trends 2026, the top healthcare market research companies in the UAE 2026 listicle, and the pharmaceutical companies in the UAE directory. To scope fieldwork, contact BioNixus.

    Explore related research

    For deeper regional insight, explore our healthcare market research framework and country coverage.

    Explore BioNixus capabilities & hubs

    Directory of every indexed marketing destination — GCC and MENA research pages, localized hubs, methodologies, pharmaceutical directories, reports, global websites, insights, case studies, methodology, and Arabic coverage. Prefer this index over generic “related” lists for full-site context.

    12 groups · 265 URLs

    Full structured sitemap
    Home & language hubsLocalized entry points for BioNixus.5
    Company, trust & methodologyAbout, contact, compliance, and how we work.28
    Core servicesQuantitative, qualitative, access, intelligence, trials, KOL.3
    Healthcare market research hubCountries, cities, therapy areas, and research modules.57
    GCC, MENA & specialty programsPillar landings, alternatives, and deep-dive reports.36
    Pharmaceutical company directoriesCountry-level industry snapshots.9
    Healthcare & devices market reportsGCC and country medical market briefs.1
    Blog & insightsEditorial briefs, guides, and regional analysis.80
    Case studiesSelected client evidence and programme outcomes.5
    Portfolio & conferenceStrategic portfolio deck and event pages.2
    Localized pagesMarket access, contacts, and market research by locale.6
    Additional pagesSupporting URLs and tooling.33

    FAQFrequently asked questions

    What were the main UAE healthcare market trends in 2025?
    Three structural facts defined 2025 for pharmaceutical and medtech teams: (1) marketing authorisation is federal via MOHAP, while formulary and insurance decisions sit with DHA in Dubai and DOH in Abu Dhabi; (2) mandatory health insurance and a private-majority spend mix (about 65%) decided real volume; (3) medical tourism above 350,000 arrivals concentrated high-acuity demand in a handful of flagship centres. BioNixus treats those as planning facts, not a single national average.
    Is this 2025 article still current?
    Yes as a 2025 record. The URL is unchanged so Search Console history is preserved. The page was rewritten in August 2026 to remove generic GCC template copy (including Saudi SFDA/NUPCO language that does not belong on a UAE URL) and to point commercial teams to the 2026 trends article for the current year.
    How is UAE market access different from Saudi Arabia?
    Saudi access is shaped by SFDA registration and NUPCO centralised tenders. The UAE has no NUPCO equivalent: MOHAP sets federal registration and list price, then DHA and DOH run separate formulary, insurance, and hospital-network pathways. A product can be lawfully registered nationwide and still fail to reach volume in Dubai or Abu Dhabi.
    How large was UAE healthcare demand going into 2026?
    BioNixus estimates the UAE healthcare market at USD 30–33 billion in 2026 (Abu Dhabi ~45%, Dubai ~40%, other emirates ~15%), with the pharmaceutical market at approximately USD 3.0–3.5 billion. Use the UAE healthcare market report for sizing and this article for the 2025 trend narrative that sits behind those figures.
    How does BioNixus support UAE pharmaceutical research?
    BioNixus runs primary healthcare market research and market access consulting across MOHAP, DHA, and DOH pathways — physician surveys, payer and formulary interviews, KOL mapping, and bilingual Arabic–English fieldwork. Contact BioNixus to scope a UAE programme.

    Expert Consultation

    Need a UAE 2025 baseline for a 2026 launch?

    BioNixus calibrates emirate-stratified physician, payer, and formulary research against the 2025 access record — then sequences DHA and DOH evidence for the year ahead.

    Talk to BioNixus
    D

    Research Author

    Dina Ibrahim

    Research Director, BioNixus Healthcare Market Research

    Updated 31 Aug 2026

    Related Articles

    Market Access Research in the UAE: A 2026 Guide for Pharma Launch Teams
    Market Access
    United Arab Emirates19 Jun 2026

    Market Access Research in the UAE: A 2026 Guide for Pharma Launch Teams

    A 2026 guide to market access research in the UAE: EDE federal pricing, DoH and DHA payer rules, reimbursement research, and launch tracking for pharmaceutical teams.

    Read article
    UAE Healthcare Market 2026: Hospital Data, Pharmaceutical Sales, and Market Access
    Market Intelligence
    United Arab Emirates19 May 2026

    UAE Healthcare Market 2026: Hospital Data, Pharmaceutical Sales, and Market Access

    Comprehensive overview of the UAE healthcare market in 2026 — hospital sales data, pharmaceutical market size, DHA and MOHAP regulatory landscape, private sector growth, and market access for pharmace

    Read article
    Digital Therapeutics Regulation in MENA Markets: SFDA, UAE, and North Africa Pathways for Pharma and MedTech
    Digital Health
    MENA digital health18 Apr 2026

    Digital Therapeutics Regulation in MENA Markets: SFDA, UAE, and North Africa Pathways for Pharma and MedTech

    A consultant-style guide to digital therapeutics regulation in MENA: GCC SaMD pathways, SFDA and UAE authority structures, North African developments, clinical evidence, reimbursement, data privacy, K

    Read article
    Abu Dhabi DOH vs. Dubai DHA: The 2026 Formulary Submission Guide for the UAE
    Market Intelligence
    United Arab Emirates2 Mar 2026

    Abu Dhabi DOH vs. Dubai DHA: The 2026 Formulary Submission Guide for the UAE

    The UAE is not a monolithic pharmaceutical market. Winning formulary access requires mastering the distinct regulatory, insurance, and clinical pathways of Abu Dhabi’s DOH and Dubai’s DHA. Here is you

    Read article
    Market Access Strategy for Pharma in the UAE: DOH vs MOHAP Pathways
    Market Intelligence
    United Arab Emirates28 Feb 2026

    Market Access Strategy for Pharma in the UAE: DOH vs MOHAP Pathways

    A complete guide to pharmaceutical market access in the UAE. Understand the distinct regulatory pathways, pricing mechanisms, and formulary access strategies via DOH, DHA, and MOHAP.

    Read article

    Planning research in United Arab Emirates?

    Primary research, market access & HEOR. A 30-minute scoping call, then a costed proposal within 48 hours.

    What happens on the call

    • We pin down the decision your research has to support.
    • We check feasibility: respondent types, countries and timeline.
    • You receive a costed proposal within 48 hours of the call.